Keywords: Stada,Grunenthal, Branded products, First-quarter 2011 results, Palexia, Tapentadol
Stada in talks to buy Grunenthal brands in Central and Eastern Europe and ME for 360 million euros; 1st-qtr results
Article | 16 May 2011
German drugmaker Stada Arzneimittel (SAZ: GR) is negotiating with family-owned Grunenthal the purchase of a branded product portfolio including the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
